Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.67 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16599480 | 0.82 | MCL1 (0.76) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL117186 | 0.80 | MCL1 (1.00) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL401039 | 0.80 | MCL1 (0.73) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL5509362 | 0.80 | CLK1 (0.58) | MCL1MEN1KMT2A | |
| SCHEMBL12868305 | 0.80 | THRB (0.58) | MCL1MAPTMEN1KMT2A | |
| SCHEMBL24198804 | 0.79 | RXFP1 (0.59) | MCL1MEN1KMT2APHGDH | |
| SCHEMBL17995256 | 0.79 | MCL1 (0.61) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL2323444 | 0.79 | MCL1 (0.71) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL5748064 | 0.79 | MCL1 (0.71) | MCL1SLC9A1MAPTMEN1NPC1 | |
| SCHEMBL2322980 | 0.79 | MCL1 (0.71) | MCL1SLC9A1MAPTMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | MONASH UNIVERSITY (AU) | 2022-01-18 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-25 | — | — | US | disclosed |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2018-01-25 | — | — | US | disclosed |
| US-9745265-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745265-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160271270-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | PFIZER INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PFIZER INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2012051708-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES, AND METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-04-26 | — | — | WO | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
| US-20090203663-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| WO-2007091046-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731967-B2 | Inhibitors of TRIM33 and methods of use | TRIM33, TRIM28, TRIM4 | MCL1 857/4885SLC9A1 4740/4885MAPT 1086/4885 |
| US-20150209445-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS | PAICS, CYTH3, CYTH2 | MCL1 4/4885SLC9A1 4321/4885MAPT 2924/4885 |
| US-11225505-B2 | Antimicrobial polymyxin derivative compounds | VIP, PNKP, PEPD | MCL1 369/4885SLC9A1 2663/4885MAPT 4514/4885 |
| US-20090203663-A1 | CHEMICAL COMPOUNDS | ITGB5, ITGB1, ITGA2B | MCL1 461/4885SLC9A1 2097/4885MAPT 3105/4885 |
| US-20160271270-A1 | BIFUNCTIONAL CYTOTOXIC AGENTS CONTAINING THE CTI PHARMACOPHORE | CCNI, TTI1, TTI2 | MCL1 130/4885SLC9A1 2009/4885MAPT 2097/4885 |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ITGA2B, ITGB1, ITGB5 | MCL1 1868/4885SLC9A1 1038/4885MAPT 3535/4885 |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | MCL1 3096/4885SLC9A1 294/4885MAPT 291/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | MCL1 3096/4885SLC9A1 294/4885MAPT 291/4885 |
| US-10196354-B2 | 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof | RORB, RORA, RORC | MCL1 2603/4885SLC9A1 3394/4885MAPT 903/4885 |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | MCL1 690/4885SLC9A1 4825/4885MAPT 3769/4885 |
| US-20180022701-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | MCL1 2603/4885SLC9A1 3394/4885MAPT 903/4885 |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | MCL1 1758/4885SLC9A1 3275/4885MAPT 2795/4885 |
| US-20150218096-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORA, RORC | MCL1 2603/4885SLC9A1 3394/4885MAPT 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.